Trial Profile
AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Feb 2023
Price :
$35
*
At a glance
- Drugs Molgramostim (Primary)
- Indications Pulmonary alveolar proteinosis
- Focus Adverse reactions; Registrational
- Acronyms IMPALA-EX; IMPALA-X
- Sponsors Savara Pharmaceuticals
- 29 Aug 2021 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 17 Feb 2021 This trial has been discontinued in Denmark.
- 02 Feb 2021 Status changed from active, no longer recruiting to completed.